NEO-CONCEPT INTL GROUP HLD-A (NCI) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:NCI • KYG6421C1208

1.1032 USD
-0.05 (-4.48%)
Last: Feb 5, 2026, 08:00 PM
Fundamental Rating

4

NCI gets a fundamental rating of 4 out of 10. The analysis compared the fundamentals against 45 industry peers in the Textiles, Apparel & Luxury Goods industry. While NCI has a great health rating, its profitability is only average at the moment. NCI has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

4

1. Profitability

1.1 Basic Checks

  • In the past year NCI was profitable.
NCI Yearly Net Income VS EBIT VS OCF VS FCFNCI Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 0 -20M -40M

1.2 Ratios

  • NCI has a Return On Assets of 7.33%. This is amongst the best in the industry. NCI outperforms 84.44% of its industry peers.
  • With a decent Return On Equity value of 17.36%, NCI is doing good in the industry, outperforming 75.56% of the companies in the same industry.
  • NCI has a better Return On Invested Capital (11.38%) than 75.56% of its industry peers.
Industry RankSector Rank
ROA 7.33%
ROE 17.36%
ROIC 11.38%
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NCI Yearly ROA, ROE, ROICNCI Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 0 -50 -100 -150

1.3 Margins

  • The Profit Margin of NCI (3.41%) is comparable to the rest of the industry.
  • NCI's Profit Margin has improved in the last couple of years.
  • NCI's Operating Margin of 4.67% is in line compared to the rest of the industry. NCI outperforms 46.67% of its industry peers.
  • In the last couple of years the Operating Margin of NCI has grown nicely.
  • With a Gross Margin value of 25.43%, NCI is not doing good in the industry: 80.00% of the companies in the same industry are doing better.
  • NCI's Gross Margin has improved in the last couple of years.
Industry RankSector Rank
OM 4.67%
PM (TTM) 3.41%
GM 25.43%
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
NCI Yearly Profit, Operating, Gross MarginsNCI Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 5 10 15 20

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. Health

2.1 Basic Checks

  • With a Return on Invested Capital (ROIC) just above the Cost of Capital (WACC), NCI is creating some value.
  • Compared to 1 year ago, NCI has about the same amount of shares outstanding.
  • NCI has a better debt/assets ratio than last year.
NCI Yearly Shares OutstandingNCI Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 1M 2M 3M 4M
NCI Yearly Total Debt VS Total AssetsNCI Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

  • An Altman-Z score of 2.54 indicates that NCI is not a great score, but indicates only limited risk for bankruptcy at the moment.
  • With a Altman-Z score value of 2.54, NCI perfoms like the industry average, outperforming 53.33% of the companies in the same industry.
  • NCI has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 2.54
ROIC/WACC1.1
WACC10.32%
NCI Yearly LT Debt VS Equity VS FCFNCI Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 0 20M -20M 40M -40M -60M

2.3 Liquidity

  • A Current Ratio of 1.85 indicates that NCI should not have too much problems paying its short term obligations.
  • NCI has a Current ratio of 1.85. This is comparable to the rest of the industry: NCI outperforms 44.44% of its industry peers.
  • A Quick Ratio of 1.70 indicates that NCI should not have too much problems paying its short term obligations.
  • NCI's Quick ratio of 1.70 is amongst the best of the industry. NCI outperforms 84.44% of its industry peers.
Industry RankSector Rank
Current Ratio 1.85
Quick Ratio 1.7
NCI Yearly Current Assets VS Current LiabilitesNCI Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • NCI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 75.16%, which is quite impressive.
  • Measured over the past years, NCI shows a quite strong growth in Earnings Per Share. The EPS has been growing by 15.35% on average per year.
  • Looking at the last year, NCI shows a quite strong growth in Revenue. The Revenue has grown by 16.75% in the last year.
  • Measured over the past years, NCI shows a decrease in Revenue. The Revenue has been decreasing by -0.68% on average per year.
EPS 1Y (TTM)75.16%
EPS 3Y15.35%
EPS 5YN/A
EPS Q2Q%34.02%
Revenue 1Y (TTM)16.75%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%-24%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NCI Yearly Revenue VS EstimatesNCI Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2021 2022 2023 2024 100M 200M 300M

More info and screens

Find the best growth stocksShow best growing peers

3

4. Valuation

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 3.34, the valuation of NCI can be described as very cheap.
  • Based on the Price/Earnings ratio, NCI is valued cheaply inside the industry as 97.78% of the companies are valued more expensively.
  • NCI is valuated cheaply when we compare the Price/Earnings ratio to 27.67, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE 3.34
Fwd PE N/A
NCI Price Earnings VS Forward Price EarningsNCI Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

  • Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of NCI indicates a rather cheap valuation: NCI is cheaper than 97.78% of the companies listed in the same industry.
Industry RankSector Rank
P/FCF N/A
EV/EBITDA 3.63
NCI Per share dataNCI EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 2 4 6 8

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • NCI does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

NEO-CONCEPT INTL GROUP HLD-A

NASDAQ:NCI (2/5/2026, 8:00:02 PM)

1.1032

-0.05 (-4.48%)

Chartmill FA Rating
GICS IndustryGroupConsumer Durables & Apparel
GICS IndustryTextiles, Apparel & Luxury Goods
Earnings (Last)N/A
Earnings (Next)N/A
Inst Owners0.83%
Inst Owner Change0%
Ins OwnersN/A
Ins Owner Change0%
Market Cap4.48M
Revenue(TTM)295.90M
Net Income(TTM)10.10M
Analysts60
Price TargetN/A
Short Float %8.84%
Short Ratio0.04
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 3.34
Fwd PE N/A
P/S 0.12
P/FCF N/A
P/OCF N/A
P/B 0.6
P/tB 0.76
EV/EBITDA 3.63
EPS(TTM)0.33
EY29.91%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS9.33
BVpS1.83
TBVpS1.45
PEG (NY)N/A
PEG (5Y)N/A
Graham Number3.69
Profitability
Industry RankSector Rank
ROA 7.33%
ROE 17.36%
ROCE 13.79%
ROIC 11.38%
ROICexc 11.59%
ROICexgc 13.25%
OM 4.67%
PM (TTM) 3.41%
GM 25.43%
FCFM N/A
ROA(3y)13.48%
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)8.04%
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3Y38.21%
OM growth 5YN/A
PM growth 3Y14.72%
PM growth 5YN/A
GM growth 3Y30.72%
GM growth 5YN/A
F-ScoreN/A
Asset Turnover2.15
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA 0
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.85
Quick Ratio 1.7
Altman-Z 2.54
F-ScoreN/A
WACC10.32%
ROIC/WACC1.1
Cap/Depr(3y)604.44%
Cap/Depr(5y)N/A
Cap/Sales(3y)2.96%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)75.16%
EPS 3Y15.35%
EPS 5YN/A
EPS Q2Q%34.02%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)16.75%
Revenue growth 3Y-0.68%
Revenue growth 5YN/A
Sales Q2Q%-24%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y45.08%
EBIT growth 3Y37.27%
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y62.89%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y100.87%
OCF growth 3Y-65.32%
OCF growth 5YN/A

NEO-CONCEPT INTL GROUP HLD-A / NCI FAQ

What is the fundamental rating for NCI stock?

ChartMill assigns a fundamental rating of 4 / 10 to NCI.


What is the valuation status for NCI stock?

ChartMill assigns a valuation rating of 3 / 10 to NEO-CONCEPT INTL GROUP HLD-A (NCI). This can be considered as Overvalued.


Can you provide the profitability details for NEO-CONCEPT INTL GROUP HLD-A?

NEO-CONCEPT INTL GROUP HLD-A (NCI) has a profitability rating of 4 / 10.